Experimental combo for stomach and bowel cancers shows early promise, but study halted

NCT ID NCT05221320

First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 27 times

Summary

This study tested two drugs, ulixertinib and hydroxychloroquine, together in 47 adults with advanced gastrointestinal cancers that have certain gene mutations (MAPK pathway). The goal was to see if the combination could shrink tumors or slow cancer growth. The trial was terminated early, so final results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Cleveland Clinic

    Cleveland, Ohio, 44195, United States

  • Massey Cancer Center, Virginia Commonwealth University

    Richmond, Virginia, 23298, United States

  • Mount Sinai

    New York, New York, 10029, United States

  • Rogel Cancer Center, University of Michigan Health

    Ann Arbor, Michigan, 48109, United States

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey, 08903, United States

  • University of Arizona Cancer Center

    Tucson, Arizona, 85719, United States

  • University of California San Francisco

    San Francisco, California, 94143, United States

  • University of Kansas Cancer Center

    Fairway, Kansas, 66205, United States

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.